A newly disclosed sGC activator in Ph. II for CKD/DKD. This month, researchers at BI reported promising preclinical results for a newly disclosed sGC activator, BI-685509, which is in several Ph. II trials including for treatment of chronic kidney disease (CKD) and diabetic kidney disease (DKD) ( NCT04736628 , NCT04750577 ). In rodents, the [...]
4 minute read
Jan. 28, 2023
BI 685509: An sGC Activator for Kidney Diseases
BI 685509
oral sGC activator Ph. II for CDK & DKD discovery not disclosed J. Pharmacol. Exp. Ther., December 6, 2022 Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
Loading...
